219 related articles for article (PubMed ID: 31740402)
1. Agonist-induced 4-1BB activation prevents the development of Sjӧgren's syndrome-like sialadenitis in non-obese diabetic mice.
Zhou J; You BR; Yu Q
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165605. PubMed ID: 31740402
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-7 receptor-α treatment ameliorates newly established Sjögren's-like exocrinopathy in non-obese diabetic mice.
Zhou J; Yu Q
Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2438-2447. PubMed ID: 29680668
[TBL] [Abstract][Full Text] [Related]
3. Disruption of CXCR3 function impedes the development of Sjögren's syndrome-like xerostomia in non-obese diabetic mice.
Zhou J; Yu Q
Lab Invest; 2018 May; 98(5):620-628. PubMed ID: 29348563
[TBL] [Abstract][Full Text] [Related]
4. Plasmacytoid dendritic cells promote the pathogenesis of Sjögren's syndrome.
Zhou J; Zhang X; Yu Q
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166302. PubMed ID: 34780913
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 enhances the Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy in mice.
Jin JO; Kawai T; Cha S; Yu Q
Arthritis Rheum; 2013 Aug; 65(8):2132-42. PubMed ID: 23666710
[TBL] [Abstract][Full Text] [Related]
6. Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction.
Sharma A; Kiripolsky J; Klimatcheva E; Howell A; Fereidouni F; Levenson R; Rothstein TL; Kramer JM
Clin Immunol; 2016 Mar; 164():85-94. PubMed ID: 26826598
[TBL] [Abstract][Full Text] [Related]
7. Alternate-Day Fasting Ameliorates Newly Established Sjögren's Syndrome-like Sialadenitis in Non-Obese Diabetic Mice.
Li D; Onodera S; Deng S; Alnujaydi B; Yu Q; Zhou J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430269
[TBL] [Abstract][Full Text] [Related]
8. Salivary-gland-protective regulatory T-cell dysfunction underlies female-specific sialadenitis in the non-obese diabetic mouse model of Sjögren syndrome.
Barr JY; Wang X; Kreiger PA; Lieberman SM
Immunology; 2018 Oct; 155(2):225-237. PubMed ID: 29750331
[TBL] [Abstract][Full Text] [Related]
9. Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.
Roescher N; Lodde BM; Vosters JL; Tak PP; Catalan MA; Illei GG; Chiorini JA
Oral Dis; 2012 Jan; 18(1):96-106. PubMed ID: 21914088
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of endogenous TNF-α in the development of Sjögren's-like sialadenitis and secretory dysfunction in non-obese diabetic mice.
Zhou J; Kawai T; Yu Q
Lab Invest; 2017 Apr; 97(4):458-467. PubMed ID: 28067896
[TBL] [Abstract][Full Text] [Related]
11. Smad4 in T cells plays a protective role in the development of autoimmune Sjögren's syndrome in the nonobese diabetic mouse.
Kim D; Kim JY; Jun HS
Oncotarget; 2016 Dec; 7(49):80298-80312. PubMed ID: 27880731
[TBL] [Abstract][Full Text] [Related]
12. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome.
Kim JW; Kim SM; Park JS; Hwang SH; Choi J; Jung KA; Ryu JG; Lee SY; Kwok SK; Cho ML; Park SH
Arthritis Res Ther; 2019 Jun; 21(1):136. PubMed ID: 31164166
[TBL] [Abstract][Full Text] [Related]
13. RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.
Tahara M; Tsuboi H; Segawa S; Asashima H; Iizuka-Koga M; Hirota T; Takahashi H; Kondo Y; Matsui M; Matsumoto I; Sumida T
Clin Exp Immunol; 2017 Feb; 187(2):213-224. PubMed ID: 27643385
[TBL] [Abstract][Full Text] [Related]
14. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.
Lodde BM; Mineshiba F; Wang J; Cotrim AP; Afione S; Tak PP; Baum BJ
Ann Rheum Dis; 2006 Feb; 65(2):195-200. PubMed ID: 15975969
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-22 Exerts Detrimental Effects on Salivary Gland Integrity and Function.
Zhou J; Onodera S; Hu Y; Yu Q
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361787
[TBL] [Abstract][Full Text] [Related]
16. Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice.
Thompson C; Jacobsen H; Pomeranz Krummel D; Nagai K; Cooke A
Autoimmunity; 2004 Dec; 37(8):549-54. PubMed ID: 15763917
[TBL] [Abstract][Full Text] [Related]
17. Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sjögren's syndrome.
Kim DS; Woo JS; Min HK; Choi JW; Moon JH; Park MJ; Kwok SK; Park SH; Cho ML
J Autoimmun; 2021 May; 119():102611. PubMed ID: 33631650
[TBL] [Abstract][Full Text] [Related]
18. Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome.
Yanagi K; Ishimaru N; Haneji N; Saegusa K; Saito I; Hayashi Y
Eur J Immunol; 1998 Oct; 28(10):3336-45. PubMed ID: 9808203
[TBL] [Abstract][Full Text] [Related]
19. Characterization of T cell receptor repertoire and anti-Ro/SSA autoantibodies in relation to sialadenitis of NOD mice.
Skarstein K; Wahren M; Zaura E; Hattori M; Jonsson R
Autoimmunity; 1995; 22(1):9-16. PubMed ID: 8882417
[TBL] [Abstract][Full Text] [Related]
20. NOD mouse model for Sjögren's syndrome: lack of longitudinal stability.
Lodde BM; Mineshiba F; Kok MR; Wang J; Zheng C; Schmidt M; Cotrim AP; Kriete M; Tak PP; Baum BJ
Oral Dis; 2006 Nov; 12(6):566-72. PubMed ID: 17054769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
